# A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A

> **NCT03105349** · PHASE4 · WITHDRAWN · sponsor: **Fundacion SEIMC-GESIDA**

## Conditions studied

- HCV

## Interventions

- **DRUG:** elbasvir/grazoprevir
- **DRUG:** Sofosbuvir
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT03105349
- **Lead sponsor:** Fundacion SEIMC-GESIDA
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-07-01
- **Primary completion:** 2017-12
- **Final completion:** 2018-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No availability of investigational medication.
- **Last updated:** 2018-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03105349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03105349, "A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03105349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*